Search Results

You are looking at 161 - 170 of 219 items for :

  • Refine by Access: All x
Clear All
Full access

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher D’Angelo, Benjamin Derman, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Jenna Snedeker, and Rashmi Kumar

treated with CHOP-R ( P ≤.015). The ORR and CR to the 3 regimens were: CHOP-R (ORR, 96%; CR, 17%); CVP-R (ORR, 88%; CR, 12%); and CP-R (ORR, 95%; CR, 0%). A higher incidence for neutropenic fever and treatment-related neuropathy were reported for CHOP

Full access

Cancer-Related Fatigue

Ann M. Berger, Amy Pickar Abernethy, Ashley Atkinson, Andrea M. Barsevick, William S. Breitbart, David Cella, Bernadine Cimprich, Charles Cleeland, Mario A. Eisenberger, Carmen P. Escalante, Paul B. Jacobsen, Phyllis Kaldor, Jennifer A. Ligibel, Barbara A. Murphy, Tracey O'Connor, William F. Pirl, Eve Rodler, Hope S. Rugo, Jay Thomas, and Lynne I. Wagner

neutropenia Thrombocytopenia (low platelets) Anemia (low red blood cells) Fever or active infection Limitations secondary to metastasis or other illnesses The exercise program itself should be individualized based on the patient's age, gender, type

Full access

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Aaron T. Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar, Amro Elshoury, Tracy I. George, Krishna Gundabolu, Elizabeth Hexner, Gabriela S. Hobbs, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Animesh Pardanani, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Brady L. Stein, Moshe Talpaz, Pankit Vachhani, Martha Wadleigh, Sarah Wall, Dawn C. Ward, Mary Anne Bergman, and Cindy Hochstetler

reductions in quality of life, functional status, and activities of daily living. 3 – 5 Constitutional symptoms (fever, night sweats, and weight loss) are more frequently reported in patients with MF compared with those with PV or ET. 3 , 5 In a landmark

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo Jr, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O’Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams Jr, Kristina Gregory, and Miranda Hughes

-cell carcinoma of the lung . J Clin Oncol 1991 ; 9 : 499 – 508 . 90 Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl

Full access

Biologic Agents in the Management of Hodgkin Lymphoma

Armin Rashidi and Nancy L. Bartlett

.8 months. The median OS was not reached after a median follow-up of 34 weeks. Fever occurred in 52% of patients. Other side effects were as expected based on other studies, and included peripheral sensory neuropathy (48%) and grade 3 to 4 neutropenia (24

Full access

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, and Hema Sundar

symptoms related to leukostasis occur. 36 Indications for initiating treatment include severe fatigue, weight loss, night sweats, and fever without infection; threatened end-organ function; progressive bulky disease (enlarged spleen or lymph nodes

Full access

Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management

Prithviraj Bose and Srdan Verstovsek

-dependent at baseline, but had a baseline hemoglobin level of less than 10 g/dL. In the second study, the spleen response rate at 24 weeks by imaging was 45.8%. 88 Most patients had a 50% or greater improvement in pruritus, cough, bone pain, fever, and night

Full access

Chemotherapy Hypersensitivity Reactions in Ovarian Cancer

Matthieu Picard, Ursula A. Matulonis, and Mariana Castells

not fit into this classification; these reactions involve fever and chills and seem to result from the nonspecific release of cytokines. 6 This article focuses mainly on the management of type I-compatible HSRs to taxanes and platinum drugs and the

Full access

NCCN Guidelines® Insights: Survivorship, Version 1.2022

Featured Updates to the NCCN Guidelines

Tara Sanft, Andrew Day, Lindsay Peterson, M. Alma Rodriguez, Shannon Ansbaugh, Saro Armenian, K. Scott Baker, Tarah Ballinger, Gregory Broderick, Wendy Demark-Wahnefried, Kristin Dickinson, Nathan Paul Fairman, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C.F. Moore, Natalie Moryl, Heather Neuman, Tracey O’Connor, Linda Overholser, Electra D. Paskett, Chirayu Patel, William Pirl, Andrea Porpiglia, Kathryn J. Ruddy, Lidia Schapira, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Eric H. Yang, Phyllis Zee, Nicole R. McMillian, and Deborah A. Freedman-Cass

trigger the desired protective immune responses due to possible residual immune deficits. 136 – 138 In addition, certain vaccines, such as those that are live attenuated (ie, MMR, oral typhoid, yellow fever, rotavirus, intranasal influenza, and varicella

Full access

NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019

Featured Updates to the NCCN Guidelines

P. Kumar Rao, Christopher Barker, Daniel G. Coit, Richard W. Joseph, Miguel Materin, Ramesh Rengan, Jeffrey Sosman, John A. Thompson, Mark R. Albertini, Genevieve Boland, William E. Carson III, Carlo Contreras, Gregory A. Daniels, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossman, Valerie Guild, Douglas Johnson, Giorgos Karakousis, Julie R. Lange, ScM, Kim Margolin, Sameer Nath, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Evan Wuthrick, Nicole R. McMillian, and Anita Engh

, polishing or refitting of prosthesis) with hydroxyapatite implants. 34 Complications of enucleation reported in the COMS during or <24 hours after surgery include pain, hemorrhage, nausea/vomiting, cardiovascular or pulmonary issues, urinary retention, fever